Drugs / Efmarodocokin Alfa
Efmarodocokin Alfa
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04539470 | Nov 2020 → Feb 2023 | acute graft versus host disease | Genentech, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Efmarodocokin Alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04539470 ↗ |
| Known as | Il 22-fc | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650250 ↗ |
| Known as | RG-7880 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650250 ↗ |
| Known as | RO-7021610 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650250 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL4650250 ↗ |
| Route | Intravenous | “administered intravenously (IV)” NCT04539470 ↗ |